Human IL-12B / NKSF2 / p40 Protein, His Tag
分子別名(Synonym)
IL12B,CLMF,CLMF2,NKSF,NKSF2,p40
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-12B, His Tag (NK2-H52H7) is expressed from human 293 cells (HEK293). It contains AA Ile 23 - Ser 328 (Accession # P29460-1).
Predicted N-terminus: Ile 23
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 36.6 kDa. The protein migrates as 44 kDa and 46 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
白細(xì)胞介素-12(IL12)也稱為自然殺傷細(xì)胞刺激因子(NKSF)、細(xì)胞毒性淋巴細(xì)胞成熟因子(CLMF),是一種由兩個(gè)獨(dú)立基因IL-12A(p35)和IL-12B(p40)編碼的異二聚體細(xì)胞因子。IL12是由樹突細(xì)胞、巨噬細(xì)胞和人類B淋巴母細(xì)胞(NC-37)在抗原刺激下自然產(chǎn)生的。IL-12參與幼稚T細(xì)胞向Th0細(xì)胞的分化,在自然殺傷細(xì)胞和T淋巴細(xì)胞的活性中起著重要作用。IL-12還具有抗血管生成活性,這意味著它可以阻斷新血管的形成。
白細(xì)胞介素-12亞基β(IL12B),也稱為NKSF2、CLMF2和P40。白細(xì)胞介素-12亞基β已被證明與IL23相互作用。產(chǎn)生IL12的細(xì)胞也分泌大量過量的單體IL12B,并且沒有表現(xiàn)出明顯的生物活性。IL12B基因的過表達(dá)已被證明與多發(fā)性硬化癥的發(fā)病機(jī)制有關(guān)。此外,研究表明,該基因的啟動(dòng)子多態(tài)性與兒童特應(yīng)性和非特應(yīng)性哮喘的嚴(yán)重程度有關(guān)。
關(guān)鍵字: IL-12B;IL-12B蛋白;IL-12B重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。